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ABSTRACT
Objectives To compare the efﬁcacy and safety of
chondroitin sulfate plus glucosamine hydrochloride
(CS+GH) versus celecoxib in patients with knee
osteoarthritis and severe pain.
Methods Double-blind Multicentre Osteoarthritis
interVEntion trial with SYSADOA (MOVES) conducted
in France, Germany, Poland and Spain evaluating
treatment with CS+GH versus celecoxib in 606
patients with Kellgren and Lawrence grades 2–3
knee osteoarthritis and moderate-to-severe pain
(Western Ontario and McMaster osteoarthritis index
(WOMAC) score ≥301; 0–500 scale). Patients were
randomised to receive 400 mg CS plus 500 mg GH
three times a day or 200 mg celecoxib every day for
6 months. The primary outcome was the mean
decrease in WOMAC pain from baseline to 6 months.
Secondary outcomes included WOMAC function and
stiffness, visual analogue scale for pain, presence of
joint swelling/effusion, rescue medication
consumption, Outcome Measures in Rheumatology
Clinical Trials and Osteoarthritis Research Society
International (OMERACT-OARSI) criteria and
EuroQoL-5D.
Results The adjusted mean change (95% CI) in
WOMAC pain was −185.7 (−200.3 to −171.1)
(50.1% decrease) with CS+GH and −186.8 (−201.7
to −171.9) (50.2% decrease) with celecoxib,
meeting the non-inferiority margin of −40: −1.11
(−22.0 to 19.8; p=0.92). All sensitivity analyses
were consistent with that result. At 6 months, 79.7%
of patients in the combination group and 79.2% in
the celecoxib group fulﬁlled OMERACT-OARSI criteria.
Both groups elicited a reduction >50% in the
presence of joint swelling; a similar reduction was
seen for effusion. No differences were observed for
the other secondary outcomes. Adverse events were
low and similarly distributed between groups.
Conclusions CS+GH has comparable efﬁcacy to
celecoxib in reducing pain, stiffness, functional
limitation and joint swelling/effusion after 6 months
in patients with painful knee osteoarthritis, with a
good safety proﬁle.
Trial registration number: NCT01425853.
INTRODUCTION
Osteoarthritis is the most common form of arthritis
in Western populations. It most frequently affects
the knee, causing joint pain, tenderness, limitations
of movement and impairment of quality of life,
resulting in a social and economic burden.1 It
accounts for a substantial number of healthcare
visits and costs in populations with access to
medical care.2 With increasing life expectancy,
osteoarthritis is anticipated to become the fourth
leading cause of disability by the year 2020.1
Standard treatment focuses on symptom relief
with analgesics and non-steroidal anti-inﬂammatory
drugs (NSAIDs), though the latter can cause serious
gastrointestinal and cardiovascular adverse effects,
leading to concerns over long-term use.3–5
Various clinical trials have been performed with
symptomatic slow-acting drugs for osteoarthritis
(SYSADOA).6–9 Speciﬁcally, the Glucosamine/chon-
droitin Arthritis Intervention Trial (GAIT) was a
randomised, double-blind, placebo-controlled
study comparing the efﬁcacy and safety of glucosa-
mine hydrochloride and chondroitin sulfate,
alone and in combination, and celecoxib for the
treatment of knee osteoarthritis.10 While no statis-
tically signiﬁcant effects were observed for the
combination group in the overall study population,
a signiﬁcant difference was observed for the combin-
ation arm in patients with moderate-to-severe
pain for the primary outcome, deﬁned as a 20%
decrease in Western Ontario and McMaster osteo-
arthritis index (WOMAC) pain score (p=0.002).
Additionally, patients with moderate-to-severe pain
showed signiﬁcant differences in the combination
versus placebo group for Outcome Measures in
Rheumatology Clinical Trials and Osteoarthritis
Research Society International (OMERACT-OARSI)
response (p=0.001), 50% decrease in WOMAC
pain (p=0.02), WOMAC pain score (p=0.009),
WOMAC function score (p=0.008), normalised
WOMAC score (p=0.017) and Health Assessment
Questionnaire pain score (p=0.03).
To conﬁrm these effects, the Multicentre
Osteoarthritis interVEntion trial with SYSADOA
(MOVES) was conducted to test whether
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chondroitin sulfate plus glucosamine hydrochloride has compar-
able efﬁcacy to celecoxib after 6 months of treatment in patients
with painful knee osteoarthritis.
METHODS
Study design
The MOVES trial was a phase IV, multicentre, non-inferiority,
randomised, parallel-group, double-blind study. Patients were
recruited consecutively by physicians in public or private prac-
tice at sites in France, Germany, Poland and Spain (see online
supplementary table S1 for a list of investigators by study site
and country).
Patients
Eligible patients were ≥40 years of age, with a diagnosis of
primary knee osteoarthritis according to the American College of
Rheumatology, with radiographic evidence (Kellgren and
Lawrence grade 2 or 3) of osteoarthritis, and severe pain
(WOMAC pain score ≥301 on a 0–500 scale) at inclusion.
Patients were excluded if they had concurrent medical or arthritic
conditions that could confound the evaluation of the index joint
or coexisting disease that could preclude successful completion
of the trial such as history of cardiovascular or gastrointestinal
events and were excluded due to use of celecoxib. The full list of
selection criteria is detailed in online supplementary table S2.
Treatment regimens and randomisation
Eligible subjects were randomised to 400 mg chondroitin sulfate
plus 500 mg glucosamine hydrochloride (Droglican, Bioiberica,
S.A., Barcelona, Spain) three times a day or 200 mg celecoxib
(Celebrex, Pﬁzer) every day for 6 months. Subjects were
assigned sequentially in a 1:1 ratio using a computer-generated
randomisation list prepared by an independent biostatistician
(GD) using proc Plan SAS System (V.9.1.3) software. Subjects
receiving combination therapy took six capsules of chondroitin
sulfate 200 mg plus glucosamine hydrochloride 250 mg per day;
those receiving celecoxib took one celecoxib 200 mg plus one
placebo capsule (in the morning) and four further placebo cap-
sules per day. To maintain the blind (among patients, physicians,
site staff and contract research organisation), celecoxib capsules
were overencapsulated and placebo capsules had an identical
appearance to the combination product. Patients were allowed
to take up to 3 g/day of acetaminophen as rescue medication,
except during the 48 h before clinical evaluation.
Outcome measures
The primary outcome measure was deﬁned as the mean decrease
in WOMAC pain subscale from baseline to 6 months. Secondary
efﬁcacy outcome measures included: stiffness and function sub-
scales of WOMAC; visual analogue scale; OMERACT-OARSI
responder index;11 presence of joint swelling/effusion (see online
supplementary table S3 for protocols for assessment); use of
rescue medication (according to diary entries and tablet counts);
patients’ and investigators’ global assessments of disease activity
and response to therapy, and health status (EuroQol-5D) at
6 months. All outcome measures were assessed at 30, 60, 120
and 180 days.
Safety outcomes included discontinuation of study treatment
due to adverse events (AEs), changes in various laboratory mea-
sures and vital signs.
Statistical analysis
The sample size was calculated to test the non-inferiority of
chondroitin sulfate plus glucosamine hydrochloride versus
celecoxib in the assessment of change in the WOMAC pain sub-
scale. With 280 patients per group, the study would have 90%
power assuming the expected difference in means was 0, the
common SD was 26 (0–100 scale), according to previous
studies,12–16 with a delta of eight units (0–100 scale),13 16 17 a
one-sided signiﬁcance level of 2.5% and assuming a 20%
dropout rate. A delta of eight units in a range from 0 to 100
(the same as a delta of 40 units in the original range from 0 to
500) was used in the study.
The main analyses were performed using the per-protocol
population, deﬁned as all randomised patients meeting the
inclusion criteria, who received study medication, had a baseline
and at least one postbaseline efﬁcacy measurement (for the
primary efﬁcacy variable) and did not have major protocol vio-
lations. In non-inferiority trials, the per-protocol set is used in
the primary analysis as it is the most conservative approach.
Additionally, the primary efﬁcacy analysis was performed
according to intention to treat to test the robustness of the
results.18 19 The safety population was deﬁned as all randomised
subjects who took at least one dose of the study medication.
Continuous efﬁcacy variables were analysed by means of a
mixed models for repeated measurements (MMRM) approach,
including time, treatment-by-time interaction and baseline value
as a covariate. The variance–covariance matrix was unstruc-
tured. For categorical variables, Fisher’s exact test was used for
between-treatment comparisons, by time-point when applicable.
Missing data in the main outcome were handled using a conser-
vative approach by imputation using the dropout reason (IUDR)
(the worst value for dropouts due to safety issues) or the last
observation carried forward approach in case of lack of efﬁcacy.
Other reasons were not imputed and were handled by the
MMRM approach, which relies on the missing at random
assumption. Sensitivity analyses were conducted using the base-
line observation carried forward (BOCF) and the MMRM with
no imputation.
The analysis was performed using SAS V.9.2 software (SAS
Institute, Cary, North Carolina, USA), and the level of signiﬁ-
cance was established at the 0.05 level (two-sided).
RESULTS
Patient characteristics
Recruitment began in September 2011 at 42 centres in France,
Germany, Poland and Spain. The study was completed in April
2013. A total of 763 patients were screened and 606 underwent
randomisation (ﬁgure 1). The main reasons for screen failure in
157 patients were high cardiovascular risk (n=36, 22.9%),
patient decision (n=31, 19.8%) and low WOMAC pain score
(n=23, 14.7%). Of the 606 subjects randomised, 568 (93.7%)
were included in the intention-to-treat analysis and 522 (86.1%)
in the per-protocol analysis. Of the 603 subjects included in the
safety population, 465 (77.1%) completed the study, without
differences between treatments (ﬁgure 1).
The mean±SD age at baseline was 62.7±8.9 years, 438
(83.9%) were women and 515 (98.7%) were Caucasian. The
overall mean WOMAC pain score was 371.3±41.6, and
Kellgren and Lawrence grade 2 changes were present in 327
(62.6%) of the subjects. The groups were well balanced at base-
line (table 1).
Clinical outcomes
Efﬁcacy
The primary and secondary efﬁcacy outcomes are detailed in
table 2 and ﬁgure 2.
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The mean change from baseline to 6 months in WOMAC
pain score was −185.7 (−200.3 to −171.1) (a decrease of
50.1%) in the chondroitin sulfate plus glucosamine group and
−186.8 (−201.7 to −171.9) (a decrease of 50.2%) in the cele-
coxib group (ﬁgure 2A). The corresponding mean difference
(95% CI) respected the non-inferiority margin of −40 units:
−1.1 (−22.0 to 19.8; p=0.92) in the main analysis. All sensitiv-
ity analyses conﬁrmed the non-inferiority conclusion (ﬁgure 3
and online supplementary table S4). There were no differences
at 6 months between treatment groups in the WOMAC stiffness
score, with a decrease of 46.9% in the combination group, com-
pared with a decrease of 49.2% in the celecoxib group
(p=0.43; ﬁgure 2B); WOMAC function score, with a decrease
of 45.5% in the combination group compared with a decrease
of 46.4% in the celecoxib group (p=0.53; ﬁgure 2C) and visual
analogue scale, with a decrease of 48.0% in the combination
group versus a decrease of 48.8% in the celecoxib group
(p=0.92; ﬁgure 2D). Similarly, there were no differences in
patients’ (p=0.51) and physicians’ (p=0.33) global assessments
of disease activity or response to therapy (p=0.74 and 0.70,
respectively). Over 70% of patients fulﬁlled the
OMERACT-OARSI criteria in both treatments from 120 days
onwards (p=0.16; ﬁgure 2E). At 6 months, both treatments
achieved a 79% response rate (p=0.91; ﬁgure 2E). Both groups
elicited a reduction from baseline >50% in joint swelling
(ﬁgure 2F), from 12.5% (33/264) to 5.9% (14/264) for chon-
droitin sulfate plus glucosamine, and from 14.0% (36/258) to
4.5% (10/258) for celecoxib (p=0.54). A similar reduction was
also seen for effusions, from 6.8% (18/264) to 3.0% (7/264)
and from 7.8% (20/258) to 4.1% (9/258), respectively
(p=0.61; ﬁgure 2G). The consumption of rescue medication
throughout the study was low and similar between treatments,
except for the ﬁrst month when use was higher in the combin-
ation group. No signiﬁcant differences were observed afterwards
(ﬁgure 2H).
Health-related quality of life
All components of the EuroQoL-5D showed improvements over
the treatment period in both groups. At 6 months, no differ-
ences were apparent between groups in terms of mobility
(p=0.16), self-care (p=0.94), usual activities (p=0.73), pain/
discomfort (p=0.60), anxiety/depression (p=0.21) or general
health status measured by the visual analogue score (p=0.54;
table 2).
Figure 1 Flow diagram of
Multicentre Osteoarthritis interVEntion
trial with SYSADOA (MOVES) patients.
Hba1c, glycated haemoglobin; ITT,
intention to treat; PP, per protocol.
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Safety
The overall proportion of subjects having at least one
treatment-emergent AE were 51.0% (155/304) in the chondro-
itin sulfate plus glucosamine group and 50.5% (151/299) in the
celecoxib group. In total, 17 of the AEs were serious, 7 (2.3%)
in the chondroitin sulfate plus glucosamine group and 10
(3.3%) in the celecoxib group. One serious AE was judged as
deﬁnitely related to the study medication (allergic dermatitis)
and one as possibly related (dizziness) (both in the celecoxib
group); three serious AEs were judged to be probably related to
the study group, two in the chondroitin sulfate plus glucosamine
group (Helicobacter pylori gastritis and allergic reaction) and
one in the celecoxib group (dermatitis psoriaform). The other
12 were deemed to be unlikely or unrelated to study medica-
tion. No deaths occurred in this study. A total of 44 of 603
(7.3%) patients discontinued the study medication due to an
AE, 22 in each treatment group (ﬁgure 1). Parameters deter-
mined from blood and urine, vital signs and physical examin-
ation were similar in both groups.
DISCUSSION
The MOVES trial found that a ﬁxed-dose combination of chon-
droitin sulfate plus glucosamine has comparable efﬁcacy to
celecoxib in reducing pain in patients with osteoarthritis of the
knee with moderate-to-severe pain after 6 months of treatment.
The reduction in pain was both clinically important and statistic-
ally signiﬁcant (50% reduction in both groups), as was the
improvement in stiffness (46.9% reduction with the combin-
ation vs 49.2% with celecoxib), and function (45.5% vs 46.4%,
respectively). Similar improvements were seen in visual analogue
scale, the pain/discomfort dimension of EuroQoL-5D and
patients’ and investigators’ assessments of disease activity and
response to therapy without differences between treatments.
Indeed, four-ﬁfths of patients met the OMERACT-OARSI
responder criteria in both groups. Other clinical symptoms,
such as swelling/effusion, improved to the same extent in both
groups and the consumption of rescue medication was similar.
These results both conﬁrm and extend those from the GAIT
study in patients with severe knee pain.
Chondroitin sulfate and glucosamine have a slow onset of
response and provide long-lasting pain relief and functional
improvement in osteoarthritis.6–9 In the current study, celecoxib
was superior to chondroitin sulfate and glucosamine at 1–4
months (in terms of WOMAC scores and Huskisson’s visual
analogue scale), but by 6 months, response to chondroitin
sulfate and glucosamine was similar to celecoxib (see online sup-
plementary table S4). Studies have demonstrated anti-
inﬂammatory effects of both glucosamine and chondroitin
sulfate. Both inhibit metalloproteinase activity, prostaglandin E2
release, nitric oxide production and degradation of glycosami-
noglycans, as well as stimulate the synthesis of hyaluronic acid
in the joint. Chondroitin sulfate stimulates collagen synthesis,
while glucosamine inhibits prostaglandin release.20–23 However,
while each substance exerts beneﬁcial effects on the processes
underlying osteoarthritis, a number of studies have demon-
strated that many of these effects beneﬁt from the synergy
observed with combined glucosamine and chondroitin sulfate
treatment.24–27 In contrast, celecoxib inhibits prostaglandin bio-
synthesis, primarily through blocking the cyclooxygenase-2
enzyme, thereby achieving rapid reduction in signs and symp-
toms of osteoarthritis of the knee,28 but it does not alter other
processes underlying the disease. This difference in the mechan-
isms of action is supported by the present results, which indicate
more substantial and faster response for celecoxib than for
chondroitin sulfate plus glucosamine up to 120 days, but by
6 months there are no signiﬁcant differences between the two
treatments across all outcomes. Indeed, the overall pain
improvement calculated using area under the curve analyses was
superior with celecoxib than with the combination (p<0.001
for the imputed per-protocol population and p=0.002 for the
imputed intention-to-treat sensitivity population).
Both treatments had a good safety proﬁle and tolerability in
this population, which excluded patients with high cardiovascu-
lar or gastrointestinal risk. Celecoxib is recognised to increase
the risk of cardiovascular thrombotic events, congestive heart
failure and major gastrointestinal events compared with
placebo,5 and, in the European Union, is contraindicated in
patients with known cardiovascular and peripheral vascular
disease. Around half of the patients in each group had at least
one AE, most of which were of mild or moderate intensity, with
only 17 events classiﬁed as serious. The observed tolerability in
both groups was as expected from previous studies, such as
GAIT.10
While the present results are in accordance with data from
other studies for the combination,10 29 30 and for celecoxib in
painful knee osteoarthritis at the same dosage,10 12–14 22 direct
comparisons are limited by differences in study designs and
Table 1 Baseline characteristics of the study population
Characteristic
Chondroitin sulfate
+glucosamine hydrochloride
(n=264)*
Celecoxib
(n=258)*
Age (years) 62.2±8.8 63.2±9.0
Women 229 (86.7) 209 (81.0)
White 260 (98.5) 255 (98.8)
Body mass index (kg/m2) 31.1±5.8 30.9±18.0
Kellgren and Lawrence radiographic reading
Grade 2 165 (62.5) 162 (62.8)
Grade 3 99 (37.5) 96 (37.2)
Most common analgesics before inclusion
Acetaminophen 74 (28.0) 77 (29.8)
Ibuprofen 45 (17.0) 37 (14.3)
Diclofenac 36 (13.4) 40 (15.5)
WOMAC score (inclusion)
Pain scale 372.0±41.8 370.6±41.4
Stiffness scale 130.2±35.0 129.5±37.2
Function scale 1131.4±242.7 1111.6±267.8
Huskisson’s visual analogue
scale (pain intensity)
72.8±15.1 73.5±15.1
Joint swelling 33 (12.5) 36 (14)
Joint effusion 18 (6.8) 20 (7.8)
Patient’s global assessment
of disease activity
69.1±17.3 69.4±16.4
Investigator’s global
assessment of disease
activity
63.2±15.5 63.3±14.7
EuroQol-5D (health-related quality of life)
Mobility 1.8±0.4 1.8±0.4
Self-care 1.4±0.5 1.4±0.5
Usual activities 1.8±0.4 1.8±0.4
Pain/discomfort 2.3±0.4 2.3±0.4
Anxiety/depression 1.7±0.6 1.6±0.6
Visual analogue scale 54.5±20.3 52.5±20.7
Data are mean±SD or n (%).
*Continuous variables are mean±SD at baseline and baseline adjusted least-square
means (95% CI) for other measurements; ordinal variables are mean±SD.
WOMAC, Western Ontario and McMaster osteoarthritis index.
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drug formulations. The only randomised double-blind study
that allows the comparison of the combination of chondroitin
sulfate plus glucosamine with celecoxib was the GAIT study.10
The data of efﬁcacy and safety in the present study are consist-
ent with those from GAIT in patients with severe knee pain.
Chondroitin and glucosamine have been recommended in
some practice guidelines for the treatment of osteoarthritis.31–33
Both chondroitin sulfate and the two commercially available
salts of glucosamine hydrochloride or sulfate are available as
prescription medicines in the European Union for the treatment
of osteoarthritis. The clinical evidence to support these medica-
tions is, however, conﬂicting.10 34–38 Consequently, current
evidence-based guidelines on the management of osteoarthritis
focus on topical treatments and oral analgesics,31 39 40 and
some39 40 advise against treatment with chondroitin sulfate and
glucosamine on the basis of lack of efﬁcacy evidence, but not on
potential harm.39 Conversely, the suboptimal efﬁcacy and possi-
bility of serious adverse drug reactions with long-term use of
analgesics, NSAIDs and opioids are well recognised.
The present study, conducted in patients with osteoarthritis of
the knee with severe pain, provides robust data to demonstrate
the long-term efﬁcacy and safety of chondroitin sulfate plus glu-
cosamine in the management of these patients, and suggests that
this combination may, in addition, offer an alternative, especially
for individuals with cardiovascular or gastrointestinal conditions
who have contraindications for treatment with NSAIDs.
This study has some limitations. The preparation of chondro-
itin sulfate plus glucosamine used has been approved as a pre-
scription drug, and the present results cannot therefore be
generalised to other compound mixtures, such as commercially
available dietary supplements in the UK and the USA, or to the
individual components themselves. As patients with known
Table 2 Primary and secondary efficacy outcomes in per-protocol population
Outcome
Chondroitin sulfate+glucosamine
hydrochloride* Celecoxib* p Value† Treatment differences‡
WOMAC pain score (imputed data on per-protocol set)
Baseline 372.0±41.8 370.6±41.4
180 days 185.8 (171.2 to 200.4) 184.7 (169.8 to 199.6) 0.92 −1.1 (−22.0 to 19.8)
Change −185.7 (−200.3 to −171.1) −186.8 (−201.7 to −171.9)
WOMAC stiffness score
Baseline 130.2±35.0 129.5±37.2
180 days 69.1 (63.3 to 74.8) 65.8 (59.9 to 71.7) 0.43 −3.3 (−11.5 to 5.0)
Change −60.4 (−66.1 to −54.7) −63.7 (−69.6 to −57.8)
WOMAC function score
Baseline 1131.4±242.7 1111.6±267.8
180 days 617.0 (570.8 to 663.2) 595.8 (548.4 to 643.2) 0.53 −21.2 (−87.3 to 45.0)
Change −504.4 (−550.6 to −458.2) −525.6 (−573.0 to −478.3)
Huskisson’s visual analogue scale
Baseline 72.8±15.1 73.5±15.1
180 days 37.9 (34.7 to 41.0) 37.6 (34.4 to 40.9) 0.92 −0.22 (−4.8 to 4.3)
Change −35.1 (−38.3 to −31.9) −35.3 (−38.6 to −32.1)
OMERACT-OARSI responder§ 188 (79.7) 175 (79.2) 0.91
Joint swelling§ 14 (5.9) 10 (4.5) 0.54
Joint effusion§ 7 (3.0) 9 (4.1) 0.61
Consumption of rescue medication (days 120–180) 31.0 (25.8 to 36.2) 29.0 (23.6 to 34.3) 0.58 −2.1 (−9.5 to 5.4)
Patients’ global assessment of disease activity
Baseline 69.1±17.3 69.4±16.4
180 days 38.3 (35.3 to 41.4) 36.9 (33.8 to 40.0) 0.51 −1.5 (−5.8 to 2.9)
Change −31.0 (−34.0 to −28.0) −32.4 (−35.6 to −29.3)
Investigators’ global assessment of disease activity
Baseline 63.2±15.5 63.3±14.7
180 days 35.3 (32.6 to 38.1) 33.4 (30.6 to 36.2) 0.33 −1.9 (−5.8 to 2.0)
Change −27.8 (−30.5 to −25.1) −29.7 (−32.5 to −26.9)
Patients’ global assessment of response to therapy at 180 days 36.8 (33.5 to 40.2) 36.0 (32.6 to 39.5) 0.74 −0.8 (−5.6 to 4.0)
Investigators’ global assessment of response to therapy 34.7 (31.6 to 37.9) 33.8 (30.6 to 37.0) 0.70 −0.9 (−5.4 to 3.6)
EuroQol-5D
Mobility 1.5±0.03 1.5±0.03 0.16
Self-care 1.2±0.03 1.2±0.03 0.94
Usual activities 1.4±0.03 1.4±0.03 0.73
Pain/discomfort 1.8±0.03 1.9±0.03 0.60
Anxiety/depression 1.4±0.04 1.3±0.04 0.21
Visual analogue scale 69.1±1.3 70.2±1.3 0.54
*Continuous variables are mean±SD at baseline and MMRM model baseline adjusted least-square means (95% CI) for other measurements; ordinal variables are mean±SD.
†MMRM model p value of treatment effect.
‡MMRM model adjusted mean (95% CI).
§n (%) and Fisher’s exact test p value.
MMRM, mixed models for repeated measurement; WOMAC, Western Ontario and McMaster osteoarthritis index.
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cardiovascular disease and those at high risk for both cardiovas-
cular and gastrointestinal disease were not included, it is not
possible to extend the safety of the combination to this popula-
tion. The study was designed as a non-inferiority trial with two
active treatment arms. The use of a placebo group was not con-
sidered appropriate for ethical and methodological reasons.
A non-inferiority trial requires that the reference treatment’s
efﬁcacy is established or is in widespread use, as is the case for
celecoxib, so that a placebo or untreated control group would
be deemed unethical.41 This is of special relevance in this spe-
ciﬁc patient population with moderate-to-severe pain.
Furthermore, the use of a placebo arm was not considered
necessary as the design of the MOVES study was similar to that
of the GAIT study, which already compared both active treat-
ments with placebo. Additionally, both treatment groups have
already demonstrated superiority compared with placebo in
former randomised controlled trials.12–15 17 29 30
These results conﬁrm that the combination of chondroitin
sulfate plus glucosamine hydrochloride has proven non-inferior
to celecoxib in reducing pain. No differences were found for
stiffness, functional limitations, joint swelling and effusion after
6 months of treatment in patients with severe pain from osteo-
arthritis of the knee, and the combination has a similar good
safety proﬁle and tolerability. This combination of SYSADOA
Figure 2 Western Ontario and McMaster osteoarthritis index (WOMAC) (A) pain, (B) stiffness and (C) function subscales, and (D) visual analogue
scale by visit; (E) Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) responder
criteria, (F) joint swelling, (G) joint effusion and (H) consumption of rescue medication, by visit. The p values compare values between treatments.
Data are least-square means±SEM. CE, celecoxib; CS+GH, chondroitin sulfate plus glucosamine hydrochloride.
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appears to be beneﬁcial in the treatment of patients with osteo-
arthritis of the knee and should offer a safe and effective alter-
native for those patients with cardiovascular or gastrointestinal
conditions.
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Figure 3 Mixed models for repeated
measurements analysis, conducted
using the following approaches for
handling missing data: (A) imputation
using drop-out reason (IUDR); (B)
baseline observation carried forward
(BOCF); and (C) available data only
(ADO). The p value is for the
superiority test. CE, celecoxib; CS+GH,
chondroitin sulfate plus glucosamine
hydrochloride; ITT, intention to treat;
PP, per protocol.
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